Lead Product(s) : Ebselen
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sound Pharmaceuticals’ IND Involving Cochlear Implantation Allowed by the FDA
Details : SPI-1005 (ebselen) is a novel anti-inflammatory Glutathione Peroxidase mimetic, an enzyme critical to hearing and balance. It is being tested for residual hearing loss reduction during and after CI.
Brand Name : SPI-1005
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 20, 2024
Lead Product(s) : Ebselen
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Redmile Group
Deal Size : $16.2 million
Deal Type : Financing
Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025
Details : The financing aims to fund the clinical development of SENS-501 (OTOF-GT) small molecule programs for the treatment and prevention of hearing loss disorders.
Brand Name : SENS-501
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 08, 2024
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Redmile Group
Deal Size : $16.2 million
Deal Type : Financing
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Redmile Group
Deal Size : $54.4 million
Deal Type : Financing
Sensorion Announces Financing With Participation From US And European Healthcare Investors
Details : Through financing, Sensorion will prioritize the development of SENS-501 ( OTOF-GT), which aims to restore hearing in individuals with Otoferlin deficiency, a prevalent form of congenital deafness.
Brand Name : SENS-501
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 09, 2024
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Redmile Group
Deal Size : $54.4 million
Deal Type : Financing
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sensorion Receives Approval to Begin Phase 1/2 Trial of SENS-501 in Europe
Details : SENS-501 (OTOF-GT) is a dual vector AAV gene therapy aiming to restore hearing in patients with otoferlin protein mutations causing severe to profound hearing loss.
Brand Name : SENS-501
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
January 19, 2024
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SENS-501
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe
Details : OTOF-GT is a dual AAV vector gene therapy development program aims to restore hearing in patients with mutations in OTOF who suffer from severe to profound sensorineural prelingual non syndromic hearing loss.
Brand Name : OTOF-GT
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 19, 2023
Lead Product(s) : SENS-501
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in The UK
Details : OTOF-GT is a dual AAV vector gene therapy development program aims to restore hearing in patients with mutations in OTOF who suffer from severe to profound sensorineural prelingual non syndromic hearing loss.
Brand Name : OTOF-GT
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 07, 2023
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : DB-OTO
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DB-OTO is a gene therapy product candidate designed to provide durable restoration (selectively express functional OTOF in the inner hair cells) of hearing to individuals born with profound hearing loss due to mutation of the OTOF gene.
Brand Name : DB-OTO
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
January 24, 2023
Lead Product(s) : DB-OTO
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AK-OTOF
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Eli Lilly
Deal Size : $1,097.0 million
Deal Type : Acquisition
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases
Details : AK-OTOF is a dual adeno-associated viral (AAV) vector-based gene therapy intended to treat patients with OTOF-mediated hearing loss by delivering transgenes encoding OTOF to the inner hair cells (IHCs) of the cochlea.
Brand Name : AK-OTOF
Molecule Type : Cell and Gene therapy
Upfront Cash : $1,097.0 million
December 01, 2022
Lead Product(s) : AK-OTOF
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Eli Lilly
Deal Size : $1,097.0 million
Deal Type : Acquisition
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SENS-401 (arazasetron), is an orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment.
Brand Name : SENS-401
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AK-OTOF
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Eli Lilly
Deal Size : $487.0 million
Deal Type : Acquisition
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
Details : Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide including lead product, AK-OTOF, a treatment of hearing loss due to mutations in the otoferli...
Brand Name : AK-OTOF
Molecule Type : Cell and Gene therapy
Upfront Cash : $487.0 million
October 18, 2022
Lead Product(s) : AK-OTOF
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Eli Lilly
Deal Size : $487.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?